The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA

Scandinavian Journal of Immunology

Volumn 72, Issue 6, 2010, Pages 554-554

  Hovden, A ^a   Appel, S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; PLACEBO;

CANCER THERAPY; CELL STIMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE SYSTEM; LETTER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; DENDRITIC CELLS; DRUG APPROVAL; HUMANS; NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78149236593     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02464.x     Document Type: Letter

References (3)

1. Reid CD, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992;149:2681-8.
2. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
3. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.